Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

EMEunice MagalhãesSCSamanta CatuenoAMAbhishek Maiti

Discussion

Loading...

Member takes

Overview

Observational analysis shows IDH1 and IDH2 protein levels predict outcomes in AML, suggesting importance in therapy selection.

Key Points

  • Higher levels of IDH1 and IDH2 correlate with better outcomes in patients with acute myelogenous leukemia, confirming prognostic value.
  • LogRank testing revealed significant differences in overall survival for mutated and wild-type IDH patients based on protein levels.
  • Analysis through differential expression highlighted specific proteins that may influence the treatment response in acute myelogenous leukemia.
  • Increased understanding of protein levels lays groundwork for targeted therapies, with implications for future CAR-T cell strategies.

Cite This Study

Magalhães et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3a6https://doi.org/10.1182/blood-2025-5270
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies2025
  2. 2Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia2025
  3. 3IDH2 R172 mutation is associated with improved survival in IDH-mutated AML/MDS patients undergoing allogeneic stem cell transplantation: A geth-TC multicenter study2025
  4. 4Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML2025
  5. 5Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia2025